Skip to main content
Gustafsson BI on Muck Rack

Gustafsson BI

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gustafsson

Contact Gustafsson, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PSD Bank Rhein-Ruhr eG

|
By Gustafsson BI, Tepper JE, Michalski JM, eds. Gunderson
| Sparda-Bank web.Börsenforum
* In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs.
Open in Who Shared View Duplicates (19) Issue with article?

PSD Bank Rhein-Ruhr eG

|
By Kunz PL, Michalski JM, Gustafsson BI, Tepper JE
| Sparda-Bank web.Börsenforum
* Phase III NETTER-2 trial met primary endpoint of improvement in progression- free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who received first line treatment with Lutathera(®) in combination with long-acting octreotide, versus high-dose long-acting octreotide alone(1,)(2) * Lutathera is the first radioligand therapy (RLT) to demonstrate clinically meaningful...
Open in Who Shared View Duplicates (43) Issue with article?
See all 2 articles